Back to top
more

Omnicell (OMCL)

(Delayed Data from NSDQ)

$29.31 USD

29.31
242,085

+0.02 (0.07%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $29.55 +0.24 (0.82%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical Info Systems

Better trading starts here.

Zacks News

Here's Why You Should Invest in AMN Healthcare (AMN) Stock Now

AMN Healthcare (AMN) continues to benefit from its broad range of services.

Zacks Industry Outlook Highlights Omnicell, Axonics and Outset Medical

Omnicell, Axonics and Outset Medical have been highlighted in this Industry Outlook article.

3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio

Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.

Change Healthcare (CHNG)-Luma Launch Patient Engagement Suite

Change Healthcare's (CHNG) latest launch is expected to significantly improve patients' healthcare journey and create a more streamlined patient experience.

Urmimala Biswas headshot

3 Medical Info System Stocks Braving Industry Headwinds

Medical Info Systems stocks like Omnicell, Inc. (OMCL), Axonics, Inc. (AXNX) and Outset Medical, Inc. (OM) are expected to gain despite pandemic-led disruptions.

Here's Why You Should Hold on to Inogen (INGN) Stock For Now

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.

Veeva Systems (VEEV) Inks Deal to Serve Rare Disease Patients

Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Veeva Development Cloud business.

Here's Why You Should Hold on to DaVita (DVA) Stock For Now

Investors remain optimistic about DaVita (DVA) due to strength in its DaVita Kidney Care and impressive overseas growth.

Privia Health (PRVA) Surges 8.1%: Is This an Indication of Further Gains?

Privia Health (PRVA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Here's Why You Should Hold on to Abiomed (ABMD) Stock For Now

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Here's Why You Should Hold on to Surmodics (SRDX) Stock For Now

Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.

Anthem (ANTM) Unveils Two Brands to Boost Whole Person Health

Anthem (ANTM) launches Carelon and Wellpoint brands to streamline its products and services portfolio as well as bring about enhanced health plans for clients and consumers.

West Pharmaceutical's (WST) Syringe System to Improve Outcome

West Pharmaceutical's (WST) new CZ syringe system size is expected to enable a simpler patient experience and aid pharmaceutical companies in providing better access to their products.

BD's (BDX) Latest Collaboration to Enhance Patient Care

BD's (BDX) new partnership is expected to increase efficiency for new clinical trials, generate evidence, support new claims for its products and streamline medical device regulatory submissions.

Here's Why You Should Hold on to Ecolab (ECL) Stock For Now

Investors continue to be optimistic about Ecolab (ECL) owing to its solid product portfolio.

CPSI vs. OMCL: Which Stock Is the Better Value Option?

CPSI vs. OMCL: Which Stock Is the Better Value Option?

Here's Why Investors Should Retain Omnicell (OMCL) Stock Now

Investors are optimistic about Omnicell's (OMCL) better-than-expected results and new launches.

Should SPDR S&P 600 Small Cap ETF (SLY) Be on Your Investing Radar?

Style Box ETF report for SLY

Should iShares Core S&P SmallCap ETF (IJR) Be on Your Investing Radar?

Style Box ETF report for IJR

Should Vanguard S&P SmallCap 600 ETF (VIOO) Be on Your Investing Radar?

Style Box ETF report for VIOO

Catalent's (CTLT) Latest Facility Expansion to Boost Capacity

Catalent's (CTLT) latest site expansion is expected to significantly boost its business.

Reasons to Retain Catalent (CTLT) Stock in Your Portfolio

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.

What's in the Cards for Medtronic (MDT) in Q4 Earnings?

Medtronic's (MDT) Cardiovascular business is expected to have gained share in both high and low power devices in Q4.